Tuberculosis Post-Allogeneic Hematopoietic Stem Cell Transplantation: Insights from a Decade-Long Nationwide Study in a Low-Incidence Setting
Posted inClinical Updates Hematology-Oncology Infectious Diseases news

Tuberculosis Post-Allogeneic Hematopoietic Stem Cell Transplantation: Insights from a Decade-Long Nationwide Study in a Low-Incidence Setting

This nationwide retrospective study in France highlights the rare but severe incidence of tuberculosis (TB) in Allo-HSCT recipients, identifying birth in high-prevalence countries as a primary risk factor and emphasizing the need for targeted latent TB screening.
Targeting the Glycan Signature: Oncofetal Chondroitin Sulfate as a Selective Vulnerability in Acute Myeloid Leukemia
Posted inClinical Updates Hematology-Oncology news Pathology & Lab Medicine

Targeting the Glycan Signature: Oncofetal Chondroitin Sulfate as a Selective Vulnerability in Acute Myeloid Leukemia

This review explores oncofetal chondroitin sulfate (ofCS) as a revolutionary AML target. Unlike traditional antigens, ofCS is absent in normal bone marrow, allowing antibody-drug conjugates to eliminate leukemia cells with minimal hematotoxicity in preclinical models.
Standard Preventive Interventions for Vasovagal Reactions Fail to Show Benefit in Massive 1.4 Million Donor Trial
Posted inHematology-Oncology news Public Health

Standard Preventive Interventions for Vasovagal Reactions Fail to Show Benefit in Massive 1.4 Million Donor Trial

The STRIDES trial, the largest of its kind, demonstrates that isotonic drinks, extended rest, modified muscle tension, and psychosocial support do not significantly reduce vasovagal reactions in blood donors compared to existing UK standard practices, suggesting that current safety protocols may already be optimized.